+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06084936

Evaluating Glofitamab Compared to Rituximab-Based Therapies for Relapsed or Refractory Mantle Cell Lymphoma

Led by Hoffmann-La Roche · Updated on 2026-10-06

182

Participants Needed

83

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of glofitamab alone compared with the choice of either rituximab plus bendamustine or lenalidomide with rituximab in patients with relapsed or refractory mantle cell lymphoma. This Phase III study aims to determine which treatment better controls the disease in adults who have already received prior therapies, including a BTK inhibitor. The study involves random assignment to one of the treatment groups to compare outcomes over time. Participants assigned to the glofitamab group will receive two intravenous doses of obinutuzumab before starting intravenous glofitamab, given in 12 cycles of 21 days each. Those in the comparator group will receive either bendamustine plus rituximab for up to six 28-day cycles or rituximab plus oral lenalidomide daily for 21 days in 28-day cycles until the disease worsens. Tocilizumab may be given intravenously as needed to manage side effects related to immune response. During the study, participants will undergo regular assessments to monitor disease progression, response to treatment, physical functioning, fatigue, and lymphoma symptoms using questionnaires and clinical evaluations. Researchers will also measure drug levels and immune responses up to 24 months after randomization. Safety and effectiveness will be closely tracked, including survival and duration of response, to understand the benefits and risks of each treatment option.

CONDITIONS

Brief Title

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Research Team

R

Reference Study ID Number: GO43878 https://forpatients.roche.com/ No attachments to email below.

F

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here